|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 100, 13-21, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
P Menasche, C Grousset, C Mouas and A Piwnica
Iron catalysis is involved in the generation of the highly cytotoxic
hydroxyl radical and in the chain reactions of subsequent lipid
peroxidation that lead to irreversible membrane damage. Assuming that
ischemically stored heart transplants may incur free radical injury at the
time of reoxygenation, we assessed the effects of the iron chelator
deferoxamine in 70 isolated isovolumic buffer-perfused rat hearts subjected
to the following protocol: cardioplegic arrest; cold (2 degrees C) storage
for 5 hours; global ischemia at 15 degrees C for 1 hour, intended to
simulate the implantation procedure; and normothermic reperfusion for 1
additional hour. During poststorage ischemic arrest, the following
techniques of myocardial protection were evaluated: hypothermia alone;
high-pressure (60 cm H2O) cardioplegia given at 0, 30, and 55 minutes of
arrest; low-pressure (30 cm H2O) cardioplegia given at 0 and 55 minutes of
arrest; and low-pressure (30 cm H2O) cardioplegia only given at 55 minutes
of arrest. Treated hearts had deferoxamine (6 mumol) added to the
cardioplegic solution used throughout the experimental time course.
Further, in the treated group subjected to the protocol of single
cardioplegic delivery at end ischemia, deferoxamine was given both in the
cardioplegic reperfusate and in the Krebs buffer over the 15 initial
minutes of reflow. Based on comparisons of postreperfusion ventricular
pressure development, maximal rate of rise of ventricular pressure, left
ventricular compliance, and coronary flow, the best myocardial protection
was afforded by deferoxamine given as an additive to single-dose
cardioplegic solution at the end of arrest and to the reperfusate during
the initial phase of reoxygenation. As the drug has no inotropic effect,
its protective action is most likely related to a decrease in catalytic
iron available for free radical production and lipid peroxidation. These
results support the hypothesis that oxidative damage may contribute to
donor heart failure and demonstrate that this form of damage can be
efficiently acted upon by iron chelation. The clinical relevance of these
data stems from the fact that deferoxamine is available for human use and
might become an effective means of improving donor heart preservation in
the setting of clinical heart transplantation.
ARTICLES
A promising approach for improving the recovery of heart transplants. Prevention of free radical injury through iron chelation by deferoxamine
Service de Chirurgie Cardio-Vasculaire, Hopital Lariboisiere, Paris, France.
This article has been cited by other articles:
![]() |
Y. Tanoue, S. Morita, Y. Ochiai, M. Hisahara, M. Masuda, Y. Kawachi, R. Tominaga, and H. Yasui INHIBITION OF LIPID PEROXIDATION WITH THE LAZAROID U74500A ATTENUATES ISCHEMIA-REPERFUSION INJURY IN A CANINE ORTHOTOPIC HEART TRANSPLANTATION MODEL J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1017 - 1026. [Abstract] [Full Text] |
||||
![]() |
J. S. Ikonomidis, V. Rao, R. D. Weisel, N. Hayashida, and T. Shirai Myocardial Protection for Coronary Bypass Grafting: The Toronto Hospital Perspective Ann. Thorac. Surg., September 1, 1995; 60(3): 824 - 832. [Abstract] [Full Text] |
||||
![]() |
Shu Tao, G. Calza, F. Lerzo, A. Virgone, N. Camassa, G. Panizzon, L. Brunelli, R. Moretti, P. Grasso, G. Ghiggeri, et al. Activation of the intracellular glutathione system by oxydative stress during cardiopulmonary bypass and myocardial perfusion Perfusion, January 1, 1995; 10(1): 45 - 50. [Abstract] [PDF] |
||||
![]() |
G. Drossos, A. Lazou, P. Panagopoulos, and S. Westaby Deferoxamine Cardioplegia Reduces Superoxide Radical Production in Human Myocardium Ann. Thorac. Surg., January 1, 1995; 59(1): 169 - 172. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |